Bardoxolone

Nomen chemicum:

(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4; 4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicene-4a-acidi carboxylici

SMILES Code:

CC(C)([C@](CC[C@@]([C@@]1(CC[C@]2(CCC(C)(C[C@]2([C@]13[H ])[H])C)C(O)=O)C)4C)5[H])C(C(C#N)=C[C@]5(C)C4=CC3=O)=O

InChi Code:

InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22- 28(5) 15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8- 13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1

InChi Key:

TXGZJQLMVSIZEI-UQMAOPSPSA-N

Keyword:

Bardoxolone, RTA 402, CCDO, RTA-402, RTA402, 218600-44-3

Solubilitas:Solutum in DMSO

Repono:0 - 4°C ad terminum brevem (dies ad septimanas), vel -20°C ad terminum longi (menses).

Descriptio:

Renum sectiones e simiarum Bardoxolone methyl-tractatorum demonstrat expressio dapibus megalin decrescentibus non obstante similis mRNA expressio per circulos. Deminutio visualista in dapibus megalin analysibus densitometricis confirmata est, quae demonstravit Bardoxolonem methyl administrationem significanter minui dapibus expressionis megalin in simia renibus. Bardoxolone yl administratio dapibus expressionis cubilini in renibus vel variantia expressio cubilini in renibus non afficit. Alvi creatinine in simiis Bardoxolone yl administrata signanter discrepavit ab ea in baseline et in animalibus in vehiculo tractatis die 28. Post 28 dies Bardoxolone yl administratione, albumin urinarium ad rationes creatinine (UACRs), ex urina 24 horarum determinata. collectiones insigniter auctae sunt cum iis quae in vehiculo animalium recipientibus sunt. Nota, UACRs decrescit 53.3% in animalibus car-tractatis et 27.9% in simiis yl-tractis Bardoxolone auctis[3]. Mures masculi C57BL/6J administrantur BARD oralis in HFD pascens (HFD/BARD), tantum victu pingui pingui (HFD), vel victu pingui pingui (LFD) per 21 septimanas pavit. Mures comparati cum LFD, mures HFD auctum habent in numero F4/80 coronarum similium structurarum (+95%, p.<0.001), quod efficaciter impeditur a BARD (−50%; p<0.01). Similiter numerus F4/80 macrophages interstitiales signanter superior est in HFD muribus per 98% (p.<0.001) cum LFD muribus et 32% (p*<0.01) comparatur cum muribus HFD/BARD[4].

Target: Nrf-2